Further pooled qualitative and quantitative analyses from a new systematic review based on individual patients data rather than on aggregate data (that are often insufficient for a thorough analysis) or from adequately powered third generation clinical trials (i.e., assessing the early use of high titer CP administered in populations of patients with inadequate antiviral response and at increased risk of developing severe COVID-19) are needed to pinpoint exactly where and when CP can give the greatest clinical benefit in COVID-19. This evidence concerns the gene CP and COVID-19.